Company Overview
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Watertown, Massachusetts, focused on developing novel therapies for serious hematologic disorders. The company's scientific foundation lies in understanding red blood cell biology — specifically heme biosynthesis (the process by which cells produce heme, the oxygen-carrying component of hemoglobin) and iron homeostasis (how the body regulates iron). By targeting these pathways, Disc Medicine aims to address diseases where current treatments are inadequate, including polycythemia vera (PV), myelofibrosis, and other bone marrow-driven blood disorders.
Business Model & Competitive Advantage
Disc Medicine's lead clinical asset is bitercept (formerly DISC-0974), an anti-hemojuvelin antibody that suppresses hepcidin — the master regulator of iron absorption — to mobilize iron for red blood cell production in conditions of functional iron deficiency. The company also advances DISC-3405, a targeting agent with a distinct mechanism. Disc Medicine went public on the Nasdaq under ticker IRON and has raised over $175M through its IPO and subsequent public offerings, funding multiple ongoing Phase 1 and Phase 2 trials. The company has assembled a leadership team with deep expertise from Acceleron Pharma, Agios Pharmaceuticals, and Blueprint Medicines.
Competitive Landscape 2025–2026
The hematology rare disease space is competitive but characterized by large unmet need: polycythemia vera affects approximately 100,000–150,000 patients in the US, and myelofibrosis affects roughly 20,000 patients, many of whom progress through existing therapies. Disc Medicine's approach — targeting the underlying biology of red blood cell production rather than symptomatic management — positions its pipeline as potentially disease-modifying, a key differentiator that supports its premium positioning in a space where Incyte and AbbVie dominate with JAK inhibitors.
Key Differentiators
Emerging Innovator
Disc Medicine is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Compare Disc Medicine with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Disc Medicine? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Disc Medicine Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Disc Medicine vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →